-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Transfer from | Medicine Guanlan
Recently, Yifang Bio announced the first clinical data of its oral KRAS G12C inhibitor in cancer patients
KRAS is one of the most frequently mutated oncogenes in human cancers.
This time, Yifang Bio presented its Phase 1 clinical data of its oral KRAS G12C inhibitor at the AACR
In another analysis of non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation, with Professor Lu Shun of Shanghai Chest Hospital as the principal investigator, 59 patients were included, of which 52 were evaluable patients.
Note: The original text has been deleted